Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

rhGAA in Patients With Infantile-onset Glycogen Storage Disease-II (Pompe Disease)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00053573
Recruitment Status : Completed
First Posted : February 3, 2003
Last Update Posted : February 5, 2014
Information provided by:

Brief Summary:
Glycogen Storage Disease Type II ("GSD-II"; also known as Pompe disease) is caused by a deficiency of a critical enzyme in the body called acid alpha-glucosidase (GAA). Normally, GAA is used by the body's cells to break down glycogen (a stored form of sugar) within specialized structures called lysosomes. In patients with GSD-II, an excessive amount of glycogen accumulates and is stored in various tissues, especially heart and skeletal muscle, which prevents their normal function. This study is being conducted to evaluate the safety and effectiveness of recombinant human acid alpha-glucosidase (rhGAA) as a potential enzyme replacement therapy for GSD-II. Patients diagnosed with infantile-onset GSD-II who are greater than 6 months old, but less than or equal to 36 months old will be studied.

Condition or disease Intervention/treatment Phase
Glycogen Storage Disease Type II Pompe Disease Acid Maltase Deficiency Disease Glycogenosis 2 Biological: Myozyme Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label, Multicenter, Multinational, Study of the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of rhGAA Treatment in Patients Greater Than 6 Months and Less Than or Equal to 36 Months Old With Infantile-Onset GSD-II
Study Start Date : February 2003
Actual Primary Completion Date : July 2006
Actual Study Completion Date : November 2006

Arm Intervention/treatment
Experimental: 1 Biological: Myozyme
20 mg/kg to 40 mg/kg qow
Other Name: Alglucosidase alfa

Primary Outcome Measures :
  1. Evaluate the safety of Myozyme [ Time Frame: 52 weeks ]
  2. Determine proportion of patients alive over the course of treatment [ Time Frame: 52 weeks ]
  3. PK profile of MZ [ Time Frame: 52 weeks ]
  4. PD profile of MZ [ Time Frame: 52 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   6 Months to 36 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • The patient or the patient's legal guardian(s) must provide written informed consent prior to any study-related procedures being performed
  • The patient must have a clinical diagnosis of infantile GSD-II as defined by: (a) the patient has/had documented (in a medical record) onset of symptoms compatible with GSD-II by 12 months of age; (b) the patient has documented GAA deficiency as illustrated by an endogenous GAA activity less than or equal to 2% of the mean of the normal range as assessed in cultured skin fibroblasts; AND (c) the patient has a Left Ventricular Mass Index greater than 2 standard deviations above the mean for age
  • The patient is greater than 6 months old and less than or equal to 36 months old at the time of the first dose of rhGAA
  • The patient and his/her legal guardian(s) must have the ability to comply with the clinical protocol

Exclusion Criteria:

  • Signs and symptoms of cardiac failure and an ejection fraction less than 40%
  • Major congenital abnormality
  • Clinically significant organic disease (with the exception of symptoms relating to GSD-II), including clinically significant cardiovascular, hepatic, pulmonary, neurologic, or renal disease, or other medical condition, serious intercurrent illness, or extenuating circumstance that, in the opinion of the Investigator, would preclude participation in the trial or potentially decrease survival
  • Use of any investigational product within 30 days prior to study enrollment
  • Received enzyme replacement therapy with GAA from any source

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00053573

Layout table for location information
United States, Florida
University of Florida College of Medicine
Gainesville, Florida, United States, 32610
United States, North Carolina
Duke University Medical Center
Durham, North Carolina, United States, 27710
United States, Ohio
Children's Hospital Medical Center
Cincinnati, Ohio, United States, 45229
Pediatrique Hopital de Brousse
Lyon, France
Rambam Medical Center
Haifa, Israel, 31096
United Kingdom
Royal Manchester Children's Hospital
Manchester, United Kingdom, M27 4 HA
Sponsors and Collaborators
Genzyme, a Sanofi Company
Layout table for investigator information
Study Director: Medical Monitor Genzyme, a Sanofi Company

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Medical Monitor, Genzyme Corporation Identifier: NCT00053573    
Other Study ID Numbers: AGLU01702
First Posted: February 3, 2003    Key Record Dates
Last Update Posted: February 5, 2014
Last Verified: February 2014
Keywords provided by Sanofi:
Glycogen Storage Disease Type II
Pompe Disease
Additional relevant MeSH terms:
Layout table for MeSH terms
Glycogen Storage Disease Type II
Glycogen Storage Disease
Metabolic Diseases
Deficiency Diseases
Lysosomal Storage Diseases, Nervous System
Brain Diseases, Metabolic, Inborn
Brain Diseases, Metabolic
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Genetic Diseases, Inborn
Lysosomal Storage Diseases
Nutrition Disorders
Metabolism, Inborn Errors
Carbohydrate Metabolism, Inborn Errors